AUTHORS
Irina Amitai, MD, Yifat Lev Buchman, PhD2, Victoria Marcu, PhD3, Maya Sasson, PhD4, May Basood, MD5, Drorit Merkel, MD6, Abraham Avigdor, MD7, Liat Shargian, MD8
AFFILIATIONS
1 Medical Center Dr. h Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, Tel Aviv University, Tel Aviv, Israel
2 Medical Center Dr. h Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
3 Medical Center Dr. h Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
4 Medical Center Dr. h Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
5 Beit Holim Assuta Tel Aviv Ramat HaHayal, Tel Aviv-Yafo, Israel
6 Medical Center Dr. h Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, Tel Aviv University, Tel Aviv, Israel
7 Medical Center Dr. h Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, Tel Aviv University, Tel Aviv, Israel
8 Medical Center Dr. h Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel, Tel Aviv University, Tel Aviv, Israel
ABSTRACT
Background: Germline CHEK2 variants are increasingly recognized in myeloid and lymphoid malignancies, but how heterozygous variants contribute to tumorigenesis remains uncertain. Prior studies found acquired somatic CHEK2 variants to be absent or rare (Stubbins 2025; Yang 2026); whether the retained allele undergoes structural disruption invisible to targeted sequencing has not been examined. We characterized a consecutive single-center cohort spanning myeloid and lymphoid malignancies and applied optical genome mapping (OGM) to assess structural second hits at CHEK2.
Methods: Consecutive patients with hematologic malignancy and a germline or presumed-germline CHEK2 variant identified through reflexive NGS at Sheba Medical Center between January 2024 and January 2026 were included (690 screened). Variants were classified by ClinVar consensus; germline status was confirmed on non-hematopoietic tissue where available or inferred from persistent heterozygous VAF. Somatic NGS was reviewed for acquired CHEK2 variants in all evaluable cases. OGM was performed in 11 cases to assess 22q11.21 copy-number loss and CHEK2-disrupting structural variants, with karyotyping for gross 22q abnormalities in the remainder.
Results: Twenty-one patients harbored a germline or presumed-germline CHEK2 variant; one additional p.Ser428Phe carrier was excluded as somatic. Median age was 54 years (range 1.6–86); 14 (67%) were male. Sixteen had myeloid malignancies (AML, MDS, MF/MPN) and five lymphoid (T-ALL, n=2; B-ALL, n=2; MPAL, n=1). Five (24%) were pediatric (1.6–15 years), all with lymphoid malignancy or MPAL. Fourteen (67%) had a prior or antecedent malignancy: six solid tumors, eight antecedent hematologic neoplasms or MPN, five therapy-related AML (categories overlapped); all pediatric and de novo MPN cases were cancer-naive. Family history of malignancy was documented in 10 patients, including concordant MPN in first-degree relatives of two, though not systematically ascertained.
The cohort was predominantly Ashkenazi Jewish and enriched for recurrent CHEK2 variants, including the Ashkenazi founder p.Ser428Phe (n=6) and a reduced-penetrance missense variant p.Ile200Thr (n=3), alongside truncating/splice pathogenic variants (Thr410fs, Thr367fs, Trp452Ter, splice-site) and seven ClinVar VUS (33%). One patient carried two germline CHEK2 variants (Thr410fs and Ile200Thr). .
No confirmed CHEK2 second hit was identified. Among 11 tumors evaluated by OGM, none showed 22q11.21 copy-number loss or a CHEK2-disrupting structural variant, including a chromothriptic genome with extensive rearrangement of chromosomes 3 and 5 but no involvement of the CHEK2 locus. Karyotyping in additional evaluable cases showed no gross 22q abnormality. No acquired somatic CHEK2 variant was detected, and the germline variant remained heterozygous (VAF ~0.47–0.52) in all but one carrier — a p.Tyr424His VUS at VAF 0.96, suggesting possible loss of the wild-type allele (under investigation). Acquired alterations were lineage-conventional (e.g., DNMT3A, IDH2, JAK2, STAG2 in myeloid; NOTCH1, PHF6 in lymphoid disease).
Conclusions: Germline CHEK2 variants spanned adult and pediatric myeloid and lymphoid malignancies. The high burden of antecedent and therapy-related malignancy, pediatric presentations, and familial clustering was compatible with an underlying predisposition phenotype, although individual causation remains uncertain and one-third of variants were VUS. These findings extend prior sequence-based studies by arguing against an additionalacquired second hit at CHEK2 and support a predominantly monoallelic predisposition model upon which lineage-conventional somatic drivers act. The possibility of haploinsufficiency or dominant negative effect will be discussed. Functional studies of the variants are plannedto determine their pathogenicity.
DISCLOSURES
Irina Amitai, MD: J&J - Honoraria; Syndax, J&J - Honoraria; Astellas - Consultancy (Includes expert testimony)